[¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients.

PLoS One 2014 5;9(2):e87629. Epub 2014 Feb 5.

LUNAM Université, 49 000, Angers, France ; INSERM UMR_S 1066 Micro et Nanomédecines Biomimétiques, Angers, France ; Université d'Angers, CHU Angers, Pôle des Spécialités Médicales et Chirurgicales Intégrées, Département de Pneumologie, Angers, France ; Université d'Angers, Equipe Pyver, Angers, France.

Purpose: The aim of this prospective study was to evaluate whether [¹⁸F]FDG-PET/CT, performed within two weeks of starting erlotinib therapy can predict tumor response defined by RECIST 1.1 criteria after 8 weeks of treatment in patients with inoperable (stage IIIA to IV) non-small cell lung cancer patients.

Patients And Methods: Three [¹⁸F]FDG-PET/CT scans were acquired in 12 patients before (5±4 days) and after 9±3 days (early PET) and 60±6 days (late PET) of erlotinib therapy. Conventional evaluation, including at least chest CT (baseline versus after 8 weeks of treatment), was performed according to RECIST 1.1 criteria. Change in [¹⁸F]FDG uptake was compared with conventional response, progression-free survival (PFS), and overall survival (OS).

Results: By using ROC analysis, the Area Under the Curve for prediction of metabolic non-progressive disease (mNP) by early PET was 0.86 (95% CI, 0.62 to 1.1; P = 0.04) at a cut-off of 21.6% reduction in maximum Standardized Uptake Value (SUVmax). This correctly classified 11/12 patients (7 with true progressive disease; 4 with true non-progressive disease; 1 with false progressive disease). Non-progressive disease after 8 weeks of treatment according to RECIST 1.1 criteria was significantly more frequent in patients classified mNP (P = 0.01, Fisher's exact test). mNP patients showed prolonged PFS (HR = 0.27; 95% CI, 0.04 to 0.59; P<0.01) and OS (HR = 0.34; 95% CI, 0.06 to 0.84; P = 0.03). Late PET analysis provided concordant results.

Conclusion: Morphologic response, PFS and OS survival in non-small cell lung cancer patients can be predicted by [¹⁸F]FDG-PET/CT scan within 2 weeks after starting erlotinib therapy.

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087629PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3914822PMC
November 2014
8 Reads

Publication Analysis

Top Keywords

erlotinib therapy
12
non-progressive disease
12
weeks treatment
12
recist criteria
12
therapy predict
8
non-small cell
8
progressive disease
8
starting erlotinib
8
lung cancer
8
cell lung
8
weeks starting
8
early pet
8
patients
6
disease
5
weeks
5
analysis area
4
area curve
4
roc analysis
4
osresults roc
4
curve prediction
4

References

(Supplied by CrossRef)
Global cancer statistics
A Jemal et al.
CA Cancer J Clin 2011
Reporting results of cancer treatment
AB Miller et al.
Cancer 1981

Similar Publications